Literature DB >> 3259286

Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus.

W J McCune1, J Golbus, W Zeldes, P Bohlke, R Dunne, D A Fox.   

Abstract

Severe systemic lupus erythematosus affecting the kidney or central nervous system may lead to organ failure or death despite treatment with high doses of corticosteroids. To evaluate the clinical and immunologic effects of intravenous cyclophosphamide in this setting, we treated nine patients with monthly intravenous infusions of cyclophosphamide for six months. A comparison of characteristics at entry and follow-up revealed improvements (by paired t-test) in creatinine clearance (66 vs. 96 ml per minute, P less than 0.001); 24-hour urinary protein level (4.11 vs. 0.90 g, P less than 0.05), Farr anti-DNA titer (43 vs. 8.5 percent, P less than 0.01); complement components C3 (894 vs. 1150 mg per liter, P less than 0.05), C4 (154 vs. 222 mg per liter, P less than 0.05), and total complement activity (CH50) (88.7 vs. 113.4 IU, P less than 0.05); and Westergren erythrocyte sedimentation rate (60.2 vs. 34.4 mm per hour, P less than 0.0005). Other manifestations of lupus improved markedly in most cases, despite a reduction in the mean daily dose of prednisone, from 45 mg at entry to 17 mg at follow-up (P less than 0.01). The numbers of lymphocytes positive for T3, T4, T8, and B1 declined progressively during treatment. At follow-up, persistent decreases were observed in the T-lymphocyte subsets, whereas the absolute number of B lymphocytes had returned to levels near base line. T-cell proliferative responses at follow-up were not significantly different from entry values, except that the response to mitogenic anti-T11 (CD2) antibodies was decreased (P less than 0.01). Our data indicate that monthly intravenous administration of cyclophosphamide was associated with a substantial amelioration of severe systemic lupus, in conjunction with discrete changes in T-lymphocyte markers and T-cell function. This was a preliminary, uncontrolled study, but the results warrant further investigation of this form of treatment.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3259286     DOI: 10.1056/NEJM198806023182203

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  51 in total

Review 1.  Initial management of proliferative lupus nephritis: to cytotoxic or not to cytotoxic?

Authors:  H M Belmont
Journal:  Curr Rheumatol Rep       Date:  1999-12       Impact factor: 4.592

2.  Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study.

Authors:  L La Mantia; M Eoli; A Salmaggi; V Torri; C Milanese
Journal:  Ital J Neurol Sci       Date:  1998-02

3.  LUPUS NEPHRITIS-A CRITICAL ANALYSIS OF 17 PATIENTS.

Authors:  P K Prasher; P P Varma; K V Baliga; S S Uppal; J S Saini
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 4.  Recognition and management of systemic lupus erythematosus.

Authors:  J O Schroeder; H H Euler
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 5.  Rheumatology.

Authors:  R A Asherson; R Cervera; D P D'Cruz; G R Hughes
Journal:  Postgrad Med J       Date:  1991-02       Impact factor: 2.401

6.  Sex-specific differences in the relationship between genetic susceptibility, T cell DNA demethylation and lupus flare severity.

Authors:  Amr H Sawalha; Lu Wang; Ajay Nadig; Emily C Somers; W Joseph McCune; Travis Hughes; Joan T Merrill; R Hal Scofield; Faith M Strickland; Bruce Richardson
Journal:  J Autoimmun       Date:  2012-02-03       Impact factor: 7.094

Review 7.  Immunotherapy of systemic sclerosis.

Authors:  Rebecca Manno; Francesco Boin
Journal:  Immunotherapy       Date:  2010-11       Impact factor: 4.196

Review 8.  Immunosuppressive therapy in autoimmune disease--a review.

Authors:  T J Counihan; C Feighery
Journal:  Ir J Med Sci       Date:  1991-07       Impact factor: 1.568

Review 9.  Kidney disease in systemic lupus erythematosus.

Authors:  J E Balow
Journal:  Rheumatol Int       Date:  1991       Impact factor: 2.631

10.  Pulse cyclophosphamide therapy for inflammatory bowel disease.

Authors:  Zsolt Barta; László Tóth; Margit Zeher
Journal:  World J Gastroenterol       Date:  2006-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.